The molecular pathology of luminal B breast tumor is characterized by ER-positive or/and PR-positive and HER-2 positive or negative but Ki − 67 > 14% [9], and endocrine therapy is effective, while molecularly targeted therapy is feasible due to partial positive HER-2 expression. This evidence concerns the gene ERBB2 and breast neoplasm.